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Introduction
Thyroid cancer is rare (3.7–4.7/100,000 population), account-
ing for less than 1% of all malignancies and 0.5% of all cancer
deaths.1–3 Of thyroid cancers, 90% are well-differentiated,
arising from follicular cells, and have an excellent prognosis
irrespective of treatment.4 Papillary thyroid cancer is the com-
monest form and accounts for at least 50% of all thyroid
malignancies. This figure is even higher in children and in
post-irradiation cases. Follicular carcinoma accounts for 15–
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25% of thyroid cancers. The peak incidence of papillary cancer
is in patients aged 30–40 years, while follicular carcinoma
occurs in a slightly older age group (35–45 years). Both carci-
nomas are three times more common in females than males.5
The objectives of treatment for thyroid cancers are to
eradicate the primary tumour, reduce the incidence of local
or distant recurrence, facilitate treatment of metastasis
and cure the maximum number of patients with minimal
morbidity. There is general agreement that surgery is the
treatment of choice, but the extent of the procedure remains
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controversial.6–9 The extent of thyroid resection for carcinoma
has generated a considerable amount of literature and
discussion. There are two schools of thought, one proposing
total thyroidectomy (total macroscopic excision of thyroidal
tissue) and the other advocating near-total thyroidectomy, in
which the surgeon deliberately leaves some remnant of thy-
roid tissue in order to avoid operative morbidity. Unfortunately,
most reports are retrospective, making it difficult to interpret
which procedure is better. A prospective randomized trial to
look into the survival difference with these two surgical ap-
proaches is almost impossible because the excellent progno-
sis of the disease requires a very long follow-up and a large
number of patients would be needed to show any meaningful
statistical differences in outcomes. For patients with low-risk
disease such as young patients with a small lesion, near-total
thyroidectomy may be adequate. For high-risk patients, those
with large, multifocal and extensive tumours, total thyroidec-
tomy followed by radioiodine ablation is recommended. Total
thyroidectomy is advocated at our centre for all patients with
well-differentiated thyroid cancer, except for those with small
lesions and at low risk. The major arguments for total thyroid-
ectomy include the possible presence of microscopic disease in
the opposite lobe, the reduced need for adjuvant radioiodine
therapy and the ability to use thyroglobulin as a postoperative
tumour marker. However, the more extensive surgery involved
in total thyroidectomy carries some extra morbidity. In pa-
tients with gross disease in both lobes of the thyroid, total
thyroidectomy is the best surgical procedure. However, in a
young individual with a small primary carcinoma, the ques-
tion will arise of whether near-total thyroidectomy is sufficient.
Surgeons need to consider potential complications when for-
mulating the surgical plan for such patients, weighing the
benefits of the aggressive approach against the potential com-
plications of radical surgery.
Most of our patients who undergo total thyroidectomy
have unseen thyroid remnants that are identifiable with post-
operative radioiodine scanning. This remaining thyroid tis-
sue should then be destroyed with radioiodine.10 If most pa-
tients require radioiodine ablation after macroscopic total
thyroidectomy, then perhaps such extensive dissection is not
necessary and surgery-related morbidity can be reduced. This
would also indicate that routine postoperative scanning is
unnecessary and all patients should undergo immediate
ablation.
Radioiodine scan to localize uptake before ablation is
usually performed using an oral radioiodine dose of 2–5 mCi.
The uptake of radioiodine is dependent on adequate stimula-
tion by thyroid-stimulating hormone (TSH), so thyroxine
replacement should be withdrawn at least a few weeks before
the scan. Between 24 and 96 hours after administration of the
diagnostic dose, whole-body scan is performed using a large-
field-of-view gamma scintillation camera fitted with a high-
energy parallel-hole collimator to give spot images of the neck
and other areas of uptake. Nevertheless, there is debate as
to whether a postoperative, pre-ablation scintigram is neces-
sary.11–13 Relatively low diagnostic doses of radioiodine may
impair the ability of the remnant tissue to take up the subse-
quent therapeutic dose of radioiodine due to sublethal radia-
tion delivered in the diagnostic dose, the so-called “stunning”
effect.14–16 There is considerable controversy concerning the
dose of radioiodine needed to achieve complete remnant abla-
tion in thyroid cancer patients.17–20
The aim of this study was to look at the completeness of
our macroscopic total thyroidectomy based on the incidence
of positive diagnostic radioiodine whole-body scan, which is
routine in our hospital after total thyroidectomy for thyroid
cancer, to determine whether bypassing the diagnostic whole-
body scan would reduce time and cost and prevent the stun-
ning effect before patients undergo radio-ablation. We also
reviewed the ablative dose of radioiodine in our local practice
and examined the complications of our thyroid cancer surgery
to date.
Patients and methods
This study was a retrospective analysis of all post-total thy-
roidectomy patients with well-differentiated thyroid cancers
referred for radioiodine ablation between September 1997
and December 2001. Most of these patients had undergone
surgery at this institution and the rest were referred from other
government and private hospitals. Demographic data were
collected and operative notes and histopathological reports
were reviewed to confirm tumour size, histological type, re-
gional lymph node metastasis and extra-thyroidal extension.
Patients were assessed during the follow-up for any surgical
complications. Patients who had incomplete surgery or did
not have a well-differentiated tumour were excluded. Of
56 patients for whom records were traced and reviewed, 40
patients were recruited.
Qualitative reports of diagnostic radioiodine whole-body
scans were reviewed. The scans were reported as either tracer
accumulation in the thyroid bed or in a regional area other
than the thyroid bed or distant accumulation. Thyroid hor-
mone replacement therapy was withdrawn for at least 4 weeks
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before the scan to allow the TSH level to rise before scanning.
The incidence of residual uptake after total thyroidectomy
was determined. Patients with positive scans subsequently
received a standard ablative dose of radioiodine (80 mCi 131I).
Ablation success was determined by radioiodine whole-body
scan 6–9 months after ablation. A successful ablation was
defined as no detectable uptake in the thyroid bed or elsewhere.
Patients with successful ablation were compared with those
without successful ablation in terms of possible predictive
factors such as primary tumour size, age, lymph node status
and evidence of extra-thyroidal extension using Fisher’s exact
test. A p value of less than 0.05 was considered significant.
Results
Of the 40 patients, 34 had undergone surgery at this institu-
tion and the remaining six were referred from other hospitals
nationwide. There were seven male and 33 female patients,
with 19 Malays (47.5%), 14 Chinese (35%), three Indian (7.5%)
and four others (10%), including Indonesian, Seranian and
other foreigners. The mean age was 38.6 years (range, 14–76
years). Most patients (37, 92.5%) had papillary thyroid car-
cinoma while the remaining three (7.5%) had follicular
carcinoma.
The mean size of the primary tumour was 3.62 cm (range,
0.5–6 cm); 82% of tumours larger than 4 cm had extra-
thyroidal extension. Tumour size and patient gender and age
were not correlated with the presence of cervical lymph node
metastases. Based on the American Joint Committee on Can-
cer (AJCC) classification, 25 patients had stage 1 disease, 10
had stage 2, four had stage 3 and one had stage 4 disease. Seven
patients underwent completion of previous hemithyroidec-
tomy, 23 underwent primary total thyroidectomy and 10
underwent total thyroidectomy with neck dissection.
All patients except one underwent pre-ablative whole-body
scan, which was positive in 37 (94.9%). The two patients with
negative scans both had small tumours (< 3 cm), no neck node
metastases and no extra-thyroidal extension. Both were fe-
males with papillary carcinoma; one had undergone comple-
tion of thyroidectomy while the other had undergone total
thyroidectomy.
The 30 patients who agreed to ablation received the stan-
dard dose of 80 mCi radioiodine. Reasons for not undergoing
radio-ablation were defaulting follow-up, refusing further
intervention and receiving radiotherapy instead. Radio-
ablation was successful in 21 patients (70%). The nine patients
who failed primary ablation were subjected to repeat ablation
at higher doses until their follow-up scans were negative. They
needed up to three ablations. Total ablative doses ranged
between 80 and 380 mCi. When patients were compared based
on the success or otherwise of initial ablation, there were no
significant differences in terms of tumour size (p = 0.69), age
(p = 1.0), lymph node status (p = 0.23) and extra-thyroidal
extension (p = 0.64) (Table).
Two post-total thyroidectomy complications were noted:
permanent hypocalcaemia and recurrent laryngeal nerve injury.
Permanent hypocalcaemia was found in 15% (n = 6) of patients,
four after total thyroidectomy and two after total thyroidec-
tomy with neck dissection. Three patients (7.5%) had hoarse-
ness of voice during follow-up. Laryngoscopy showed evidence
Table. The predictive factors for standard 80 mCi radioiodine ablation
Predictive factors
Standard 80 mCi radioiodine ablation
Total p
Successful (n = 21) Not successful and > 80 mCi required (n = 9)
Tumour size
   < 4 cm 11 (65%) 6 (35%) 17 0.691
   * 4 cm 10 (77%) 3 (23%) 13
Age
   < 45 years 17 (71%) 7 (29%) 24 1.000
   * 45 years 4 (67%) 2 (33%) 16
Lymph node metastasis
   Nil 11 (85%) 2 (15%) 13 0.229
   Present 10 (59%) 7 (41%) 17
Extra-thyroidal extension
   Nil 17 (74%) 6 (26%) 23 0.640
   Present 14 (57%) 3 (43%) 17
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of vocal cord palsy in keeping with recurrent laryngeal nerve
injury. All three patients had large primary tumours with
intraoperative evidence of extensive local infiltration to
muscles, jugular veins and encasing the recurrent laryngeal
nerve.
Discussion
This retrospective study allows the reviewer to look into the
local data in Malaysia that were not previously available. There
are limited data from similar studies in other Asian countries.
The results of this study are helpful in better understanding
thyroid cancer in Malaysia and in reaching a common proto-
col for the management of all thyroid cancers.
Although the number of patients in this study was small,
it was sufficient to achieve the study objectives. The sample
size was about the same as in most other studies.21 Our
institution has an endocrine unit that takes thyroid cancer
patients from all over Malaysia, so 15% of the study sample was
referred from other hospitals.
The male-to-female ratio was 1:5, which is comparable to
other studies of thyroid cancer, which report ratios of 1:3 and
1:9.21–23 There is a higher incidence of thyroid cancer in
females than males. However, gender is not a prognostic in-
dicator.23,24 Wanebo et al found that mortality from thyroid
cancer was significantly lower in female patients who had
undergone more extensive surgery than females who had
undergone lobectomy.23
Most of the study population was Malay (47.5%), followed
by Chinese (35%), foreigners (10%), and Indians (7.5%). This
reflects the population in Malaysia, which consists mainly of
Malays followed by Chinese.
The largest age group in this study was 20–30 years old, and
the mean age was 38.6 years, which is comparable to that in
other studies. In Chao et al’s study, ages ranged from 20 to 60
years with a mean of 39 years.21 In Grigsby et al’s study, the
range was 9–76 years and the mean was 42 years.22 An age of
more than 40 years increases the likelihood of cancer death
and recurrence.23 Hence, age is considered in the prognostic
scoring systems AGES (age, grade, extent, size), AMES (age,
metastases, extent, size) and MACIS (metastasis, age, com-
pleteness of resection, invasion, size). Patients older than 50
years are generally categorized as high risk.24 In our study, 23%
of patients were more than 50 years old.
From histology, 93% of tumours were papillary carcinoma
and 7% were follicular carcinoma. The incidence of papillary
carcinoma being higher than that of follicular carcinoma is
comparable to the finding from Beenken et al’s study: 64%
papillary carcinoma and 36% follicular carcinoma.6
The size of the tumour is an important factor in the
prognostic scoring systems AGES, AMES and MACIS. A tu-
mour size of more than 1.5 cm increases the risk of death and
recurrence.23 Tumour size is important in AJCC TNM staging.
Most tumours in this study (68%) were 1–4 cm, 30% were larg-
er than 4 cm and 2% were less than 1 cm. This indicates that
more effort should be made to detect small tumours (< 1 cm).
Successful early detection of thyroid cancer helps in surgery
and improves prognosis. However, there is still controversy of
whether total thyroidectomy or less than total thyroidectomy
is sufficient for tumours of less than 4 cm.
In all, 27% of patients had extra-thyroidal extension, but
82% of tumours larger than 4 cm had extra-thyroidal extension.
Extra-thyroidal extension is an important factor in the prog-
nostic scoring systems AGES, AMES and MACIS. In TNM
staging, patients with T4 disease (extending beyond the thy-
roid capsule) belong to a high-risk group with a long-term (20-
year) survival rate of only 57%.24 This group of patients needs
total thyroidectomy and radioiodine therapy. If unilateral
lobectomy is performed for papillary thyroid cancer, the inci-
dence of contralateral recurrence is less than 5%, even though
the incidence of microscopic multicentric disease can be as
high as 40–70%.24
More than half of patients (55%) had evidence of neck
lymph node metastasis. No relationship was found between
tumour size and the incidence of lymph node metastasis.
Tumour size was not a predictor of neck lymph node metastasis.
Regional lymph node metastasis is one of the factors in the
prognostic scoring systems AMES and MACIS. In the TNM
staging classification, N1 represents lymph node metastasis.
The risk of recurrence is higher in this group of patients.23
Beasley et al showed that patients with neck node metastasis
outside the central compartment of the neck have an approxi-
mately six-fold risk of developing recurrence, mostly in the
neck.25 They reported no significant differences in nodal me-
tastasis when gender, family history of thyroid disease and
history of radiation exposure were considered.
Most patients (63%) had stage 1 disease, 25% had stage 2,
10% had stage 3 and 2% had stage 4 disease. One patient had a
large papillary thyroid carcinoma with distant metastasis in
the lung. Patients older than 45 years with nodal metastasis are
considered to have stage 3 disease, and those with distant
metastasis are considered to have stage 4 disease. These older
patients have a poorer prognosis than those younger than 45
years.
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Surgeries performed were total thyroidectomy (57%), to-
tal thyroidectomy with neck dissection (25%) and completion
thyroidectomy (18%). Wanebo et al had 35% total thyroid-
ectomies, 30% near- or subtotal thyroidectomies and 35%
lobectomies in their thyroid cancer series.23 After postoper-
ative 131I ablation, they report 10-year survival rates of 82% in
patients who had undergone total thyroidectomy, 78% in
those who had undergone subtotal thyroidectomy and 89% in
lobectomy patients. The authors concluded that total thyroid-
ectomy did not significantly alter the outcome in patients with
thyroid cancer compared with the lesser procedures of subto-
tal thyroidectomy or lobectomy.
Of patients who underwent pre-ablation whole-body scan,
94.9% had tracer detected in the thyroid bed or at an extra-
thyroid site. Only 5.1% of patients had a negative scan, all of
whom had a preoperative tumour size of less than 3 cm, no
extra-thyroidal involvement and no lymph node metastasis.
Utiger suggests routine pre-ablation 131I scanning to detect
any remaining thyroid tissue so that it can be destroyed by
radioiodine ablation.10 However, Kim et al report a false-
positive 131I whole-body scan in chronic parotitis26 and Coover
reports that a false-positive total-body scan can be caused by
benign thyroid tissue after 131I ablation.27 Hypofunctioning of
residual tissue may be suppressed under euthyroid conditions,
protecting it from ablation. This tissue may be stimulated by
high TSH levels and begin accumulating 131I, which can pro-
duce a false-positive result. We did not detect any false-positive
scans in our study population. The stunning effect of pre-
ablative 131I can decrease the therapeutic effect of subsequent
ablation. Gerard and Cavalieri demonstrated that the effec-
tiveness of ablation is affected by stunning.28 The absorbed
radiation dose depends on the scanning dose administered,
the volume of target tissue and the kinetics of radioiodine in
the tissue. Gerard and Cavalieri suggested using 123I, which
carries less risk of stunning. The importance of and require-
ment for pre-ablation scanning need to be reviewed in future
because 95% of patients have positive scans despite extensive
surgery. The advantages of bypassing pre-ablation scan should
be considered: avoiding the stunning effect of pre-ablation
scanning and reducing the cost of investigation, number of
patient visits and time to radio-ablation. Klerk et al concluded
that high-dose radioiodine ablation without a prior diagnos-
tic scintigram results in a high rate of successful ablation.11
This prevents repeat treatment with 131I and reduces the cost
of the procedure and the hypothyroidism burden to patients.
Utiger explained the reasons for postoperative ablation:10
microscopic carcinoma foci in the thyroid remnant can be
destroyed because they receive radiation from adjacent nor-
mal thyroid tissue; if carcinoma recurs, it is likely to be detect-
able by radioiodine scanning because there is no more normal
thyroid tissue; some carcinoma outside the thyroid bed may be
detectable and treated; and, after all normal thyroid tissue has
been destroyed, serum thyroglobulin becomes a better marker
of recurrent carcinoma.
In our institution, a standard dose of 80 mCi is used for
primary radioiodine ablation. This dose was sufficient in 70%
of patients, but 30% of patients required repeated ablation
at higher doses. Some patients needed up to three ablative
doses, and maximum total dose was 390 mCi. Hence, in our
institution, the effective dose is between 80 and 390 mCi. In
the USA, 29 mCi is the maximum dose that can be given to a
patient without admission.10 In Stael et al’s study, 12 patients
needed 25–150 mCi (mean, 44 mCi).29 Two patients with lung
metastasis were treated with up to five doses at a total of 300
mCi. In Taube and Lundell’s study of radioiodine dosage, 63%
of patients had successful ablation with 30 mCi, 77% with 50
mCi, 73.7% with 90 mCi and 76.7% with 155 mCi.17 They
concluded that the optimum dose to the thyroid remnant is
about 50 mCi (about 30,000 cGy), as higher doses do not
appear to yield a higher ablation rate. Johansen et al did not
find any difference between low- and high-dose 131I adminis-
tration in the number of doses needed for complete ablation of
residual functioning thyroid tissue.18 However, Arslan et al
used 170 mCi of radioiodine in 242 patients; a single treat-
ment was successful in 74.3% and a second treatment was
successful in 17%, giving a success rate of 91.3% with two
treatments.12 They did not use pre-ablative 131I diagnostic
scintigraphy, but used ultrasound to measure the thyroid
remnant volume, which was significantly different (higher
doses were required in larger remnants) (p = 0.04) in those who
had successful ablation compared with those who did not.
They concluded that fixed high-dose 131I treatment is clini-
cally feasible with an acceptable dose underestimation rate,
and ultrasound-determined thyroid remnant volume pro-
vides a more accurate and reproducible result.12
We did not look into the side effects of radioiodine ablation,
which may be dose dependent and may also be found at low
doses. Lin et al reported that the side effects of low-dose (40
mCi) oral radioiodine ablation included xerostomia, nausea
(5.35%), gastralgia (3.57%), pain in the thyroid bed, tenderness
over the parotid gland and submandibular gland, change in
taste, and vomiting (1.78%).30 These effects occur because high
concentrations of iodine in the salivary gland can cause
sialadenitis after treatment. The maximum reactions occur
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between 24 and 48 hours after therapy and resolve completely
within 1 week. The authors suggest that for patients with large
remnants, low-dose rather than high-dose 131I ablation should
be chosen to avoid frequent or severe local side effects.
This study also looked into the relationship of tumour
size, age, lymph node status and extra-thyroidal extension
with successful radioiodine ablation. The total 131I dose needed
for successful ablation is significantly higher in males than
females.12 Patients with higher postoperative thyroglobulin
levels and those with a higher stage of disease also require
higher doses. There are no correlations between remnant
thyroid volume, regional or distant metastases, histopathol-
ogy and the total 131I dose needed.12 In this study, we did not
determine the postoperative thyroglobulin level, which may
be useful to predict the required dose.
Successful ablation was achieved with standard-dose
radioiodine (80 mCi) in 64% of patients with tumours of less
than 4 cm and in 77% of those with tumours of more than 4 cm.
This difference was not significant. We did not use the ultra-
sound-determined thyroid remnant volume to predict the
required radioiodine dose, as in Arslan et al’s study.12
The success rate with 80 mCi 131I was higher in patients
aged less than 45 years (71%) than in those aged more than 45
years (67%). This may be due to better responsiveness to
treatment and prognosis in those less than 45 years old. The
difference was not statistically significant, which may be due
to the small sample size.
Patients without evidence of lymph node metastasis had a
higher success rate with 80 mCi radioiodine ablation (85%)
than those with lymph node metastasis (58%). This may sug-
gest that patients with lymph node metastasis are more resis-
tant to radioiodine ablation and may need a higher dose.
However, this difference was not significant.
Patients without extra-thyroidal extension had a higher
success rate with the 80-mCi ablative dose (74%) than those
with extra-thyroidal extension (57%). This may mean that
patients with extra-thyroidal extension need a higher dose.
The difference was not significant.
This study also looked into the complications of sur-
gery for thyroid cancer. Permanent hypoparathyroidism was
found in 15% of patients, who needed long-term calcium
supplementation. This was slightly higher than in other
similar studies, which reported rates of 10%, 9%, 4% and
0.2%.23,31–33 In this study, most patients with permanent
hypoparathyroidism had undergone total thyroidectomy,
although a few had undergone total thyroidectomy with neck
dissection. The aggressiveness of surgery did not predict
permanent hypoparathyroidism. Flynn et al found hypocal-
caemia in 51% of patients after total thyroidectomy, 39% after
subtotal thyroidectomy and 22% after lobectomy, but the
relationship between hypocalcaemia and the extent of surgery
was not significant.31
Our rate of postoperative recurrent laryngeal palsy (7%)
was slightly higher than that in other studies, which reported
rates of 6.6%, 4%, 2.9%, 1% and 1%.23,31,32,34,35 These patients
had larger tumours with extensive local infiltration to the
surrounding structures. In this situation, injury to the nerve is
inevitable to achieve good surgical clearance. Less aggressive
surgery and radioiodine ablation of the remnant may offer a
feasible alternative. Bergamaschi et al found a higher inci-
dence of recurrent laryngeal nerve injury after total thyroidec-
tomy with node dissection than without node dissection.34 Lo
et al reported that only 1% of patients who had postoperative
unilateral cord paralysis were recognizable during operations,
indicating the difficulty of preventing nerve injury in the
enthusiasm of performing aggressive surgery.35 Other com-
plications such as wound infection, haematoma, bleeding
and airway obstruction were not seen in this study.
Conclusion
Almost all patients have positive residual scintigraphy scan of
the thyroid bed after total thyroidectomy. Bypassing this pre-
ablative scan can avoid the stunning effect, resulting in better
radio-ablation and reducing investigation cost and patient
time. The present ablative dose of 80 mCi is effective. The
patients referred to this tertiary institution usually have large
tumours with local infiltration. Hence, aggressive surgery to
achieve a clearer surgical margin should be replaced by postop-
erative radioiodine ablation to avoid unwanted postoperative
complications.
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